Muhammed Hamza Muslumanoglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Muhammed Hamza Muslumanoglu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Ahmet Uludag
Department of Medical Genetics, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey
1 shared publicationDerya Uzun
Department of Medical Genetics, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey
1 shared publicationEmre Tepeli
Department of Medical Genetics, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey
1 shared publicationEngin Atlı
Department of Medical Genetics, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey
1 shared publicationKemal M. Canturk
Department of Medical Genetics, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey
1 shared publicationMehmet Turgut
Department of Urology, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey
1 shared publication
Latest Publications
- Open Access
- 31 August 2022
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 68 (8) , 8-12
Investigation of the cytotoxic, anti-proliferative and anti-angiogenic effects of Toluhydroquinone on Caco-2 cell line
Colorectal cancer is one of the most common types of cancer in the world. The treatment options for colorectal carcinoma generally consist of surgery, radiotherapy and chemotherapy. The drug resistance to chemotherapy agents used in the current cancer treatment has brought about the finding of new drug molecules from some plant and aquatic species in the treatment approaches. Some species of aquatic biota create novel biomolecules as potential drugs for cancer and other diseases. Toluhydroquinone belongs to these groups of biomolecules and it shows anti-oxidative, anti-inflammatory and anti-angiogenic properties. In this study, we tested the cytotoxic and anti-angiogenic effects of Toluhydroquinone on Caco-2(Human colorectal carcinoma cell line) cells. It was observed that the amount of closure of the wound space, colony forming ability (in vitro cell survivability) and formation of tubule-like structures in matrigel decreased in comparison to the control group. As a result of this study, Toluhydroquinone has cytotoxic, anti-proliferative and anti-angiogenic properties on the Caco-2 cell line.
- 31 August 2022
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 68 (8) , 8-12
Open AccessInvestigation of the cytotoxic, anti-proliferative and anti-angiogenic effects of Toluhydroquinone on Caco-2 cell line
Colorectal cancer is one of the most common types of cancer in the world. The treatment options for colorectal carcinoma generally consist of surgery, radiotherapy and chemotherapy. The drug resistance to chemotherapy agents used in the current cancer treatment has brought about the finding of new drug molecules from some plant and aquatic species in the treatment approaches. Some species of aquatic biota create novel biomolecules as potential drugs for cancer and other diseases. Toluhydroquinone belongs to these groups of biomolecules and it shows anti-oxidative, anti-inflammatory and anti-angiogenic properties. In this study, we tested the cytotoxic and anti-angiogenic effects of Toluhydroquinone on Caco-2(Human colorectal carcinoma cell line) cells. It was observed that the amount of closure of the wound space, colony forming ability (in vitro cell survivability) and formation of tubule-like structures in matrigel decreased in comparison to the control group. As a result of this study, Toluhydroquinone has cytotoxic, anti-proliferative and anti-angiogenic properties on the Caco-2 cell line.
- 1 October 2009
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 13 (5) , 641-645
The Analysis of the Relationship Between A1298C and C677T Polymorphisms of the MTHFR Gene with Prostate Cancer in Eskisehir Population
Prostate cancer is the most common cause of cancer deaths in men and is a major health problem worldwide. Methylene tetrahydrofolate reductase (MTHFR) plays an important role for folate metabolism and is also an important source for DNA methylation and DNA synthesis (nucleotide synthesis). The objective of this study was to investigate the relationship between the A1298C and C677T polymorphisms of the MTHFR gene and prostate cancer in the Turkish population. In our study, 93 prostate cancer patients between the ages of 50–89 and a control group of 166 benign prostate hyperplasia patients were evaluated. C677T and A1298C polymorphism ratios were compared among these two groups, and an analysis was made to see if there is a statistically meaningful difference. In this study, it has been observed that C677T polymorphism of the MTHFR gene produces no statistically significant difference for T allele frequency and the genotype frequency in prostate cancer patients and male controls with benign prostate hyperplasia not having prostate cancer, whereas it has been observed that A1298C polymorphism produces a statistically significant difference for C allele frequency in prostate cancer patients and controls and that it also produces a statistically marginal significance for genotype frequencies.
- 1 October 2009
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 13 (5) , 641-645
The Analysis of the Relationship Between A1298C and C677T Polymorphisms of the MTHFR Gene with Prostate Cancer in Eskisehir Population
Prostate cancer is the most common cause of cancer deaths in men and is a major health problem worldwide. Methylene tetrahydrofolate reductase (MTHFR) plays an important role for folate metabolism and is also an important source for DNA methylation and DNA synthesis (nucleotide synthesis). The objective of this study was to investigate the relationship between the A1298C and C677T polymorphisms of the MTHFR gene and prostate cancer in the Turkish population. In our study, 93 prostate cancer patients between the ages of 50–89 and a control group of 166 benign prostate hyperplasia patients were evaluated. C677T and A1298C polymorphism ratios were compared among these two groups, and an analysis was made to see if there is a statistically meaningful difference. In this study, it has been observed that C677T polymorphism of the MTHFR gene produces no statistically significant difference for T allele frequency and the genotype frequency in prostate cancer patients and male controls with benign prostate hyperplasia not having prostate cancer, whereas it has been observed that A1298C polymorphism produces a statistically significant difference for C allele frequency in prostate cancer patients and controls and that it also produces a statistically marginal significance for genotype frequencies.